These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39196570)

  • 1. Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1.
    Lin MJ; Yao H; Vera K; Patel E; Johnson M; Caroline P; Ramos J; Mehta J; Hu X; Blakeley JO; Romo CG; Sarin KY
    JAMA Dermatol; 2024 Oct; 160(10):1091-1098. PubMed ID: 39196570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1.
    Dance B; Dardare A; Fleming J; Siow SF; Schlub TE; Crawford H; Saunderson RB; Wong C; Berman Y
    J Dermatol; 2024 Aug; 51(8):1050-1059. PubMed ID: 38923593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.
    Maguiness S; Berman Y; Rubin N; Dodds M; Plotkin SR; Wong C; Moertel C;
    Neurology; 2021 Aug; 97(7 Suppl 1):S25-S31. PubMed ID: 34230204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.
    Dhaenens BAE; van Dijk SA; Fertitta L; Taal W; Wolkenstein P; Oostenbrink R
    J Patient Rep Outcomes; 2024 May; 8(1):52. PubMed ID: 38811427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults.
    Fertitta L; Bergqvist C; Armand ML; Moryousef S; Ferkal S; Jannic A; Ravaud P; Tran VT; Ezzedine K; Wolkenstein P
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1359-1366. PubMed ID: 35412677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
    Ly I; Romo CG; Gottesman S; Kelly KM; Kornacki D; York Z; Lee SY; Rhodes SD; Staedtke V; Steensma MR; Blakeley JO; Wolkenstein P
    J Invest Dermatol; 2023 Aug; 143(8):1388-1396. PubMed ID: 37294242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1.
    Jiang C; McKay RM; Lee SY; Romo CG; Blakeley JO; Haniffa M; Serra E; Steensma MR; Largaespada D; Le LQ
    J Invest Dermatol; 2023 Aug; 143(8):1369-1377. PubMed ID: 37318402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mast Cells in Human Cutaneous Neurofibromas: Density, Subtypes, and Association with Clinical Features in Neurofibromatosis 1.
    Kallionpää RA; Ahramo K; Martikkala E; Fazeli E; Haapaniemi P; Rokka A; Leivo I; Harvima IT; Peltonen J; Peltonen S
    Dermatology; 2022; 238(2):329-339. PubMed ID: 34237737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Clinicopathologic Study on the Role of Estrogen, Progesterone, and Their Classical and Nonclassical Receptors in Cutaneous Neurofibromas of Individuals With Neurofibromatosis 1.
    Rozza-de-Menezes RE; Almeida LM; Andrade-Losso RM; de Souza Vieira G; Siqueira OHK; Brum CI; Riccardi VM; Cunha KS
    Am J Clin Pathol; 2021 Apr; 155(5):738-747. PubMed ID: 33289020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex Vivo Patient-Derived Explant Model for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas.
    Grit JL; Turner L; Essenburg CJ; Gallik KL; Dischinger PS; Shurlow ND; Pate MJ; Graveel CR; Steensma MR
    J Invest Dermatol; 2024 Sep; 144(9):2052-2065.e8. PubMed ID: 38395106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life.
    Wolters PL; Burns KM; Martin S; Baldwin A; Dombi E; Toledo-Tamula MA; Dudley WN; Gillespie A; Widemann BC
    Am J Med Genet A; 2015 Sep; 167A(9):2103-13. PubMed ID: 25976979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.
    Cannon A; Pichard DC; Wolters PL; Adsit S; Erickson G; Lessing AJ; Li P; Narmore W; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR;
    Neurology; 2021 Aug; 97(7 Suppl 1):S15-S24. PubMed ID: 34230202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous neurofibromas in the genomics era: current understanding and open questions.
    Allaway RJ; Gosline SJC; La Rosa S; Knight P; Bakker A; Guinney J; Le LQ
    Br J Cancer; 2018 Jun; 118(12):1539-1548. PubMed ID: 29695767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous neurofibromas: Current clinical and pathologic issues.
    Ortonne N; Wolkenstein P; Blakeley JO; Korf B; Plotkin SR; Riccardi VM; Miller DC; Huson S; Peltonen J; Rosenberg A; Carroll SL; Verma SK; Mautner V; Upadhyaya M; Stemmer-Rachamimov A
    Neurology; 2018 Jul; 91(2 Suppl 1):S5-S13. PubMed ID: 29987130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Immune Cell Populations of Cutaneous Neurofibromas in Neurofibromatosis 1.
    Kallionpää RA; Peltonen S; Le KM; Martikkala E; Jääskeläinen M; Fazeli E; Riihilä P; Haapaniemi P; Rokka A; Salmi M; Leivo I; Peltonen J
    Lab Invest; 2024 Jan; 104(1):100285. PubMed ID: 37949359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysfunctional coping is related to impaired skin-related quality of life and psychological distress in patients with neurofibromatosis type 1 with major skin involvement.
    Bottesi G; Spoto A; Trevisson E; Zuccarello D; Vidotto G; Cassina M; Clementi M
    Br J Dermatol; 2020 Jun; 182(6):1449-1457. PubMed ID: 31329288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin.
    Rice FL; Houk G; Wymer JP; Gosline SJC; Guinney J; Wu J; Ratner N; Jankowski MP; La Rosa S; Dockum M; Storey JR; Carroll SL; Albrecht PJ; Riccardi VM
    PLoS One; 2019; 14(5):e0216527. PubMed ID: 31107888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas.
    Staedtke V; Topilko P; Le LQ; Grimes K; Largaespada DA; Cagan RL; Steensma MR; Stemmer-Rachamimov A; Blakeley JO; Rhodes SD; Ly I; Romo CG; Lee SY; Serra E
    J Invest Dermatol; 2023 Aug; 143(8):1378-1387. PubMed ID: 37330719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.
    Ferner RE; Thomas M; Mercer G; Williams V; Leschziner GD; Afridi SK; Golding JF
    Health Qual Life Outcomes; 2017 Feb; 15(1):34. PubMed ID: 28193237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of cutaneous neurofibromas with carbon dioxide laser: Technique and patient experience.
    Peltonen S; Jannic A; Wolkenstein P
    Eur J Med Genet; 2022 Jan; 65(1):104386. PubMed ID: 34768015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.